{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3933, 
        3960
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3398, 
        3407
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3918, 
        3927
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3127, 
        3150
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3245, 
        3261
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6719, 
        6739
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6741, 
        6749
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3281, 
        3308
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3310, 
        3320
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        658, 
        662
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        1081, 
        1085
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3323, 
        3327
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3671, 
        3675
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3848, 
        3852
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6693, 
        6697
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3514, 
        3533
      ]
    }, 
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Gemma", 
      "__extent": [
        3802, 
        3821
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        546, 
        575
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        577, 
        594
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6637, 
        6663
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6665, 
        6683
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3381, 
        3389
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3909, 
        3917
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4336, 
        4337
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        663, 
        669
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        1086, 
        1092
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3328, 
        3334
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3390, 
        3397
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3663, 
        3669
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6685, 
        6691
      ]
    }
  ], 
  "Positive Findings Phraseology (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6357, 
        6367
      ]
    }
  ], 
  "Primary Origin of Neoplasm (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6368, 
        6381
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3336, 
        3341
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3689, 
        3694
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6711, 
        6716
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        598, 
        600
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        1069, 
        1071
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        2655, 
        2657
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3320, 
        3322
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3511, 
        3513
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nPID|1||^^^^SS^~11111111^^^^PI^|ALTERNATE ID|TEST^PATIENT^A||19500601|M||2054-5^Black or African American^CDC^^^|1234 Test Road^^ALBANY^NY^12201||^^^^^222^1234567|||||||\nORC|RE||111A1111111||||||||||||||||||Ordering Facility Name^^L|2222 W. Test Road^^Test^TX^77025|^^^^^111^1234567||\nOBR|1||111A1111111|^^^111111^Pathology Report^L|||201705301335|||||||20090115||Ordering Provider Name||||||20170530|||F|||||||\n\n\n\n\n\n\nPath report.gross observation\n\nGross description: \n A. Intraoperative Consultation:  Received: fresh  Specimen: left breast lumpectomy 12:00  Pathologic Evaluation: surgeon called to reevaluate margin  Diagnosis: cancel immediate gross evaluation of margins due to request from surgeon to review specimen for orientation, per surgeon upon his review medial and lateral margins were incorrectly positioned (switched)  Communicated to: Dr. Sankar at 1:49 PM on 07/27/2017, Dana Baker M.D.  Tissue submitted: not applicable \n A. Labeled: left breast lumpectomy 12:00 \n Time in fixative:  12:58 PM \n Cold Ischemic Time: 22 minutes Total formalin fixation time 8 hours \n Type of specimen: excision \n Location of specimen: left \n Size of specimen: 8.6 (anteriorposterior) by 5.0 (superiorinferior) by 2.3 (mediallateral) centimeter \n Skin: not present \n Direction of compression: mediallateral \n Needle localization: yes, 1 \n Orientation of specimen: skin, the deep, cranial and caudal metallic markers use for orientation (see above) \n Superior = blue Inferior = green Medial = yellow Lateral = orange Posterior = black Anterior/Superficial = red \n \n Plane of sectioning: anteriorposterior \n Biopsy site: present with metallic clip \n Presence/absence of discrete mass: ill-defined slightly firm tan area with necrosis and hemorrhage \n Number of discrete masses/biopsy area : 1 \n Size(s) of mass(es): 2.6 x 1.8 x 2.3 cm \n Description of mass(es): ill-defined slightly firm tan with necrosis and hemorrhage \n Distance between masses/clips: not applicable \n Distance of mass(es)/ biopsy site/clip to surgical margins: inferior-0.2 cm, medial-0.5 cm, lateral-0.2 cm, anterior-4.3 cm in the deep-1.5 cm \n Description of remainder of tissue: yellow lobulated fibrofatty \n Other remarkable features: none noted \n Tissue submitted for special investigation: not applicable \n Block summary: 1-Entire mass/biopsy site area (1-2, 3-4, 5-6, 7-8, 9-10, 11-12-entire mass area from anterior to margins posterior respectively) (cassette 5 containing metallic clip) 13-perpendicular anterior margin 14-perpendicular deep margin \n B. Labeled: Sentinel node #1 \n Tissue fragment(s): 1 \n Size: 2.1 x 1.5 x 0.5 cm \n Description: focally blue tinged and predominantly fatty replaced lymph node candidate, bisected \n Entirely submitted in 1 cassette(s). \n \n \n \n /XDB\n\n\nPayment procedure\n\nCPT                            .883071, 883072, W20061, W20532, 883601, 883602, 883603\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C50.812\n\n\nPath report.relevant Hx\n\nPre-operative diagnosis: Cancer left breast\nPost-operative diagnosis: Same as pre-op \n \n \n .\nClinical history: None provided .\n\n\nPath report.final diagnosis\n\nDiagnosis:A. LEFT BREAST, 12:00; NEEDLE-LOCALIZED EXCISION: - RESIDUAL INVASIVE MAMMARY CARCINOMA, 7 MM. - SURGICAL MARGINS NEGATIVE. - BIOPSY SITE CHANGES, MARKER CLIP PRESENT. - SEE SUMMARY BELOW. \n B. SENTINEL LYMPH NODE; EXCISION: - NO TUMOR SEEN IN ONE LYMPH NODE (0/1). \n \n INVASIVE CARCINOMA OF THE BREAST: Complete Excision Specimens InvolvedA: Breast, left, lumpectomy, 12:00 B: Sentinel node, 1 \n SPECIMEN Procedure:   Excision with image-guided localization Lymph Node Sampling:   Sentinel lymph node(s) Specimen Laterality:   Left TUMOR Presence of Invasive Carcinoma:  Histologic Type: Invasive carcinoma with ductal and lobular features (\"mixed type carcinoma\") Histologic Grade:  Glandular (acinar) / tubular differentiation: Score 3 (< 10% of tumor area forming glandular / tubular structures) Nuclear pleomorphism: Score 2 (cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape) Mitotic rate: Score 1 (<=3 mitoses per mm2) Overall grade: Grade 2 (scores of 6 or 7) Ductal Carcinoma In Situ (DCIS):  Negative for DCIS Tumor Size / Focality:  Tumor size: size of largest invasive carcinoma: Greatest dimension of largest focus of invasion > 1 mm: 7mm Tumor focality:   Single focus of invasive carcinoma Tumor Extent Macroscopic and Microscopic Extent of Tumor Skin:   Specimen does not contain skin Skeletal muscle:  Specimen does not contain skeletal muscle Accessory Tumor Findings Lymph-Vascular Invasion: Not identified Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy: In the breast: Probable or definite response to presurgical therapy in the invasive carcinoma In the lymph nodes: Negative for lymph node metastases and prominent fibrous scarring in the nodes MARGINS Invasive Carcinoma: Margins negative for invasive carcinoma Distance from closest margin: Distance is < 1 mm Closest Negative Margin(s):  Lateral Ductal Carcinoma In Situ (DCIS):  DCIS not present in specimen LYMPH NODES Regional Lymph Nodes:  Number of Sentinel Nodes Examined: Specify number 1 Number of lymph node(s) examined: Number 1 Lymph node involvement: All lymph nodes are negative STAGE (pTNM) TNM Descriptors:  y (post treatment) Primary Tumor (Invasive Carcinoma) (pT):   pT1b: tumor > 5 mm but <= 10 mm in greatest dimension Regional lymph nodes (pN) (choose a category based on lymph nodes received with the specimen; immunohistochemistry and / or molecular studies are not required) Modifier: (sn): only sentinel node(s) evaluated. if 6 or more nodes (sentinel or nonsentinel) are removed, this modifier should not be used. Category (pN): pN0: no regional lymph node metastasis identified histologically Distant Metastasis (pM): Not applicable - pM cannot be determined from the submitted specimen(s) Comment(s): Per report the tumor from the original biopsy is morphologically distinct from the residual tumor seen in the present specimen. Immunohistochemistry was performed to exclude a metastasis. The findings in summary: Mammoglobin and GCDFP-15 positive confirming breast origin; TTF1 and PAX8 negative. The controls worked appropriately. Given these findings, ER, PR, and HER-2/neu IHC is obtained and results will be issued in an addendum. \n \n XDB/08/04/2017 **********************************************************************\n\n\nPath report.site of origin\n\nMaterial submitted: Breast, left, lumpecotmy, 12:00\n\n\nPath report.comments\n\nComment:CASE: PATIENT: Final Diagnosis performed by  Electronically signed 8/3/2017 10:18:00AM \n \n The electronic signature indicates that the named Attending Pathologist has evaluated the specimen \n Technical component performed at LabCorp, 1447 York Court, Burlington, NC 27215 Lab: 800-762-4344 Dir: William F. Hancock, MD \n Professional component performed at LabCorp, Alamance Regional Medical Center, 1240 Huffman Mill Rd, Burlington, NC 27215 Lab: 336-538-7833 Dir: Tara C. Rubinas, MD \n \n \n Breast Biomarker Reporting Template Specimens InvolvedA: Breast, left, lumpectomy, 12:00 \n Breast, Biomarker Reporting Template BREAST BIOMARKER TESTS Test(s) Performed: Estrogen Receptor (ER) Results: NEGATIVE Internal controls present and ER positive (as expected) Test Type:   FDA cleared (Ventana) Primary Antibody:  SP1 Progesterone Receptor (PgR) Results: POSITIVE  Range: 1-10% Test Type:   FDA cleared (Ventana) Primary Antibody:  1E2 HER2 (ERBB2) by Immunohistochemistry (IHC) Results: Negative (Score 0) Percentage of Cells with Uniform Intense Complete Membrane Staining: 0% Test Type:   Food and Drug Administration (FDA) cleared (DAKO) Primary Antibody:  HercepTest METHODS Cold Ischemia and Fixation Times: Meet requirements specified in the latest version of ASCO / CAP guidelines Cold ischemia time (mins)::  22 Time of fixation (hours)::  8 Testing performed on block number(s) (specify):: A8 Fixative: Formalin Image Analysis:   Not performed \n \n \n \n \n Addendum #1 performed by \n Electronically signed 8/4/2017 1:31:05PM \n \n \n Technical component performed at LabCorp, 1447 York Court, Burlington, NC 27215 Lab: 800-762-4344 Dir: William F. Hancock, MD \n Professional component performed at LabCorp, Alamance Regional Medical Center, 1240 Huffman Mill Rd, Burlington, NC 27215 Lab: 336-538-7833 Dir: Tara C. Rubinas, MD .\n\n\n"
}